(Q34418714)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

chronic renal insufficiency

17 March 2020

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Mario Cozzolino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Marc G Vervloet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Ziad A Massy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Vincent M Brandenburg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Pablo Ureña-Torres

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jordi Bover

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

David Goldsmith

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

CKD-MBD Working Group of ERA-EDTA

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

1 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

427-436

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24795256%20AND%20SRC:MED&resulttype=core&format=json

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Relationship between osteoporosis and cardiovascular disease in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Arterial calcification in chronic kidney disease: key roles for calcium and phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

FGF23 protein expression in coronary arteries is associated with impaired kidney function.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Klotho converts canonical FGF receptor into a specific receptor for FGF23

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Calcium regulates FGF-23 expression in bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Effects of dietary phosphate and calcium intake on fibroblast growth factor-23

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

FGF23 induces left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

A protective role for FGF-23 in local defence against disrupted arterial wall integrity?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Arterial klotho expression and FGF23 effects on vascular calcification and function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Update on Wnt signaling in bone cell biology and bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Wnt signaling in cardiovascular physiology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Sclerostin and Dickkopf-1 in renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The role of BMPs in bone anabolism and their potential targets SOST and DKK1.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

High bone density due to a mutation in LDL-receptor-related protein 5

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

High bone mass in mice expressing a mutant LRP5 gene

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Activation of Wnt/β-catenin pathway in monocytes derived from chronic kidney disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

LRP6 mutation in a family with early coronary disease and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Wnt signalling in smooth muscle cells and its role in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteoporosis and adynamic bone in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Romosozumab in postmenopausal women with low bone mineral density.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteocalcin: skeletal and extra-skeletal effects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Endocrine regulation of energy metabolism by the skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The role of osteocalcin in human glucose metabolism: marker or mediator?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteoid osteoma is an osteocalcinoma affecting glucose metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Vitamins K and D status in stages 3-5 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone: formation by autoinduction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Purification and characterization of other distinct bone-inducing factors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone morphogenetic proteins: multifunctional regulators of vertebrate development

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Arterial calcifications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

BMPs and their clinical potentials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone morphogenetic proteins in vascular calcification

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Molecular mechanisms of vascular calcification: lessons learned from the aorta

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Matrix GLA protein and BMP‐2 regulate osteoinduction in calcifying vascular cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

A role for smad6 in development and homeostasis of the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

TGF-β/BMP pathways and the podocyte

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Evolving importance of kidney disease: from subspecialty to global health burden

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Osteoporosis--a risk factor for cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Arterial calcification and bone physiology: role of the bone-vascular axis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Emerging role of circulating calcifying cells in the bone-vascular axis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021

Update on fibroblast growth factor 23 in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970059-2

7 January 2021